VERDESO® Foam Eczema Treatment
VERDESO® Foam (desonide) Foam, 0.05%
Effective Treatment for Mild to Moderate Atopic Dermatitis
VERDESO® Foam is effective and well tolerated in patients 3 months and older with mild to moderate atopic dermatitis.2
Low-Potency Corticosteroid
VERDESO® Foam offers a low-potency corticosteroid (desonide 0.05%) in a vehicle that may improve patient compliance.2
Safe for Kids
VERDESO® Foam was tested in clinical trials, in subjects as young as 3 months old.2
Easy to Apply
VERDESO® Foam is easy to apply to multiple body areas, including the face and intertriginous areas. VERDESO® Foam spreads easily and quickly absorbs into the skin leaving it feeling soft and smooth.2
Patient Preferred Treatment
More than 70% of patients surveyed* reported a preference for VERDESO® Foam vs other topical medications.1
* A patient post-study questionnaire (N=581) was administered at the Week 4 evaluation during the phase 3 clinical trial to determine patient preferences regarding topical medications.
† Results based on the proportion of patients who would comply at least 75% of the time with the specified formulation twice a day for a month.
VersaFoam-EF™ Vehicle
VersaFoam-EF™, the delivery vehicle for VERDESO® Foam, offers the cosmetic elegance of a fine skin care product that disappears quickly into the skin and leaves it feeling soft and smooth.2
Safety Information
VERDESO® Foam is for the treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. Treatment should not exceed 4 consecutive weeks.
VERDESO® Foam is contraindicated in patients who are hypersensitive to desonide or to any of the ingredients in this preparation.
In clinical trials, the most frequent treatment-related adverse events occurred at the application site (6%). Systemic absorption of topical corticosteroids, including VERDESO® Foam, has produced reversible HPA-axis suppression.